Method of blocking vascular leakage using an anti-ANG2 antibody

Patent metadata

Field	Value
Publication number	US-9902767-B2
Application number	US-201414446256-A
Country	US
Kind code	B2
Filing date	Jul 29, 2014
Priority date	Jul 29, 2013
Publication date	Feb 27, 2018
Grant date	Feb 27, 2018

Abstract

A method for the prevention and/or treatment of a disease accompanied by vascular leakage and/or vascular inflammation comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and forms a complex with a Tie2 receptor and Ang2.

First claim

What is claimed is:

1. A method of suppressing vascular leakage or vascular inflammation, comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need thereof, wherein the anti-Ang2 antibody or antigen-binding fragment thereof comprises a polypeptide (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a polypeptide (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2, a polypeptide (CDR-H3) comprising the amino acid sequence of SEQ ID NO: 3, a polypeptide (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4, a polypeptide (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5, and a polypeptide (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6.

2. The method of claim 1 , wherein the subject has vascular leak syndrome, acute respiratory distress syndrome, acute lung injury, or diabetic vascular complication.

3. The method of claim 1 , wherein the subject has a vascular infection.

4. The method of claim 1 , wherein the anti-Ang2 antibody or an antigen-binding fragment thereof increases the activity of Tie2 by increasing phosphorylation of Tie2 receptor.

5. The method of claim 1 , wherein the anti-Ang2 antibody or an antigen-binding fragment thereof increases phosphorylation of at least one selected from the group consisting of Akt, eNOS, and MAPK1 42/44.

6. The method of claim 1 , wherein the anti-Ang2 antibody or an antigen-binding fragment thereof comprises a heavy chain variable region including the amino acid sequence of SEQ ID NO: 7 and a light chain variable region including the amino acid sequence of SEQ ID NO: 9.

7. The method of claim 1 , wherein the anti-Ang2 antibody or an antigen-binding fragment thereof is produced from a hybridoma deposited with accession number KCLRF-BP-00295.

8. The method of claim 1 , further comprising administering Ang2 to the subject.

9. A method of treating sepsis characterized by vascular leakage or vascular inflammation, comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need thereof comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof to a subject in need thereof, wherein the anti-Ang2 antibody or antigen-binding fragment thereof comprises a polypeptide (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a polypeptide (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2, a polypeptide (CDR-H3) comprising the amino acid sequence of SEQ ID NO: 3, a polypeptide (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4, a polypeptide (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5, and a polypeptide (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6.

10. The method of claim 9 , wherein the anti-Ang2 antibody or an antigen-binding fragment thereof increases phosphorylation of at least one selected from the group consisting of Akt, eNOS, and MAPK1 42/44.

11. The method of claim 9 , wherein the anti-Ang2 antibody or an antigen-binding fragment thereof comprises a heavy chain variable region including the amino acid sequence of SEQ ID NO: 7 and a light chain variable region including the amino acid sequence of SEQ ID NO: 9.

12. The method of claim 9 , wherein the anti-Ang2 antibody or an antigen-binding fragment thereof is produced from a hybridoma deposited with accession number KCLRF-BP-00295.

13. The method of claim 9 , further comprising administering Ang2 to the subject.

Assignees

• Samsung Electronics Co Ltd

Inventors

• Lee Hyo Seon
• Kim Kyung Eun
• Oh Seung Ja
• Han Sang Yeul

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C07K2317/74

  Inducing cell proliferation · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/22 Primary

  against growth factors {; against growth regulators} · CPC title